Edwards Lifesciences : First Quarter 2024 Fact Sheet

Investor Fact Sheet

March 2024

Company Overview

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, and works to improve patient outcomes and enhance lives. Edwards has been advancing therapies to treat patients suffering from structural heart disease for more than 60 years, and this large and growing area is the company's specialty. Headquartered in Irvine, Calif., Edwards' life saving innovations treat advanced cardiovascular disease and are sold in more than 100 countries. Edwards has manufacturing operations in North America, Europe, Singapore and the Caribbean.

Unique Innovation Strategy

Innovation Pioneer breakthrough technologies with compelling evidence

Leadership Lead groundbreaking standards of care through trusted relationships

Focus Singular focus on large unmet needs of structural heart and critically ill patients

Poised for Long-Term Success

• Unwavering patient-focused culture motivates and guides our global team
• Credibility and trust with clinicians, regulators, payors and patients
• Transforming patient care drives growth and secures bright future

Quick Facts

Global Headquarters	Irvine, CA, USA
Worldwide Employees	~20,000
Website	edwards.com
Stock Information (as of March 31, 2024)
Stock Symbol	EW
Stock Exchange	NYSE
Stock Price	$95.56
Shares Outstanding	604.1M
Market Capitalization	$57.7 B
Total Employee Ownership	Approximately 4%

Major Product Lines

Transcatheter Aortic Valve Replacement In partnership with physicians worldwide, Edwards continues to lead the development of minimally invasive heart valve technologies

enabling a streamlined procedure with excellent outcomes, rapid discharge and improved quality of life for patients with severe aortic stenosis. Through significant investment in technology advancement and clinical evidence, Edwards strives to further expand the treatment options for patients with severe aortic stenosis.

Transcatheter Mitral and Tricuspid Therapies Edwards is making significant investments in the development of a differentiated portfolio of repair and replacement therapy

options designed to treat mitral and tricuspid valve diseases.

Surgical Structural Heart

Edwards is committed to being the partner of choice for cardiac surgeons and relentlessly pioneering cardiac surgical innovation to improve the lives of patients globally. Edwards is the world's leading manufacturer of surgical tissue heart valve replacement and repair therapies.

Critical Care Edwards is a world leader in hemodynamic monitoring systems used to measure a patient's heart function and fluid status across care settings. The

complete hemodynamic portfolio helps clinicians make proactive clinical

decisions and plays an important role in enhancing patient recovery.

March 2024

FINANCIAL PERFORMANCE

Non-GAAP Diluted Earnings Per Share

			$2.48	$2.51
		$2.22
$1.86	$1.86
2019	2020	2021	2022	2023

R&D Investment (in millions)

			$945	$1,072
		$903
$753	$761
2019	2020	2021	2022	2023

Q1 2024

Sales by Product Line

TAVR63%

Surgical17%

Critical Care

16%

TMTT5%

Percentages may not total due to rounding

Q1 2024

Sales by Geographic Location

United States

59%

Europe23%

Japan7%

Rest of the World 11%

Non-GAAP: Excludes special charges and/or acquisitions and stock option expensing

INVESTOR RELATIONS CONTACT

[phone]

[e-mail] Main 1-800-4-A-HEART

Edwards' 5-Year Stock Performance as of March 31, 2024

n EW: 49%	n S&P 500 ​Healthcare Equipment: 21%	n S&P 500: 90%
250
200
150
100
50
0
Mar-19	Mar-20	Mar-21	Mar-22	Mar-23	Mar-24

Product Innovations

Transcatheter Aortic Valve Replacement Edwards is the global leader in transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIAsystems, are catheter-based approaches for treating patients who have severe symptomatic aortic stenosis. The proven SAPIEN family of valves is commercially available in over 75 countries and are the most widely implanted transcatheter heart valves in the world with over one million patients lives impacted since launch.

Edwards' most recently introduced SAPIEN 3 Ultra RESILIA system features RESILIA, an advanced class of tissue technology with unique anti-calcification properties, further elevating the performance of the SAPIEN 3 platform. This technology builds on Edwards' 40 years of leadership in tissue technology and durability. The SAPIEN 3 Ultra RESILIA system is also the only transcatheter heart valve to offer dry tissue storage. Additionally, the Edwards SAPIEN 3system and Alterrasystem offer a minimally invasive option for pulmonary valve replacement for patients with congenital heart disease.

The next generation SAPIEN X4 system is in development. Studies across our SAPIEN portfolio of TAVR devices in other patient populations are also continuing to enroll.

Transcatheter Mitral and Tricuspid Therapies Edwards remains focused on three key value drivers to unlock the significant long-term opportunity for patients: a portfolio of differentiated therapies; positive clinical trial results to support approvals and adoption; and favorable real-world clinical outcomes. Based on deep learnings the company has achieved from clinical trial and real-world experiences, Edwards has carefully constructed a strategic portfolio of leading transcatheter technologies to provide both repair and replacement solutions for Mitral and Tricuspid patients:

• EVOQUEtranscatheter tricuspid replacement system is currently commercially available in the U.S. and Europe
• PASCAL Precisiontranscatheter valve repair system for mitral and tricuspid regurgitation received CE Mark in Europe, and FDA approval for Degenerative Mitral Regurgitation patients in the U.S. and is currently in clinical trials for Functional Mitral Regurgitation patients and Tricuspid repair
• SAPIEN M3(a) transfemoral transcatheter mitral replacement system is currently in clinical studies

Surgical Structural Heart Edwards is the global leader in surgical heart valve repair and tissue valve replacement with our RESILIA tissue valve innovations. The MITRIS RESILIAmitral valve is designed specifically for the higher pressures and anatomy of the mitral valve position. The INSPIRIS RESILIAaortic valve is the only valve with VFit technology to expand for potential future valve-in-valve procedures, and is the leading surgical aortic tissue valve globally. The KONECT RESILIAaortic valved conduit is the first and only pre-assembled, tissue valved conduit designed for complex Bentall procedures where the aortic valve, root and ascending aorta are replaced.

Critical Care Edwards' decision support solutions for clinicians include monitoring tools and noninvasive sensors. HemoSphereadvanced monitoring platform, in combination with ForeSight tissue oximetry system, allows for a comprehensive view of tissue oximetry and advanced hemodynamics. The first-of-its-kindAcumen HPI softwareindicates the likelihood of a patient trending toward a low blood pressure event.

CAUTION: The SAPIEN M3 System consists of investigational devices, limited by Federal (United States) law to investigational use. These devices are not available for marketing or commercial sale.

This document contains forward-looking statements that are based on estimates, assumptions and projections. Important factors that could cause results to differ materially from those expected by management may be found in documents filed by the company with the Securities and Exchange Commission. Some figures are not prepared in accordance with Generally Accepted Accounting Principles (GAAP). Visit edwards.com for a reconciliation of the differences between the GAAP and non-GAAP figures.

Edwards, Edwards Lifesciences, the stylized E logo, 1-800-4-A-Heart, Acumen, Acumen HPI, Alterra, Edwards SAPIEN, Edwards SAPIEN M3, Edwards SAPIEN X4, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, Edwards SAPIEN 3 Ultra RESILIA, EVOQUE, ForeSight, HemoSphere, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS RESILIA, PASCAL, PASCAL Precision, RESILIA, SAPIEN, SAPIEN M3, SAPIEN X4, SAPIEN 3, SAPIEN 3 Ultra, SAPIEN 3 Ultra RESILIA, and VFit are trademarks of Edwards Lifesciences Corporation.

© 2024 Edwards Lifesciences. All rights reserved

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com